89985-88-6Relevant academic research and scientific papers
ALKYLBORONIC ACIDS AS ARGINASE INHIBITORS
-
Page/Page column 101, (2020/08/22)
Provided are alkylboronic acids as arginase inhibitors represented by formula (I), or a pharmaceutically acceptable salt, stereoisomer, tautomer, or prodrug thereof and a pharmaceutical composition comprising said compounds.
HETEROCYCLIC COMPOUNDS AS ARGINASE INHIBITORS
-
Page/Page column 66; 67, (2019/07/13)
The present invention relates to heterocyclic compounds as arginase inhibitors, in particular to a compound represented by Formula (I), or a pharmaceutically acceptable salt, stereoisomer or tautomer, or prodrug thereof and a pharmaceutical composition comprising said compound.
HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS
-
Page/Page column 52, (2010/06/15)
The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS
-
Page/Page column 38-39, (2009/10/30)
The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS
-
Page/Page column 34, (2008/06/13)
The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS
-
Page/Page column 49-50, (2008/06/13)
The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
PROCESSES AND INTERMEDIATES FOR PREPARING CYSTEINE PROTEASE INHIBITORS
-
Page/Page column 63, (2010/10/20)
The present invention is directed to a novel process for preparing certain cysteine protease inhibitors.
SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS
-
Page/Page column 58, (2010/11/24)
The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
SULFONAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS
-
Page/Page column 73, (2008/06/13)
The present invention is directed to compounds of formula ( I ) that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them. Wherein R3 is-alkylene-SO2NR5R6.
HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS
-
Page/Page column 62, (2008/06/13)
The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
